Global Alliance for Tb Drug Development Inc

What it reported doing in 2024

Research and development - tb alliance is a not-for-profit product development partnership (pdp), uniquely positioned to leverage a global network of public and private partners to most efficiently advance tb drug development. A pdp builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. Pdps retain direct management oversight of their projects, though much of the laboratory and clinical work is done through external research facilities and contractors. We combine the research and development expertise of our staff with the skills and resources of our partners to harness the most promising science wherever it may exist around the world. This model minimizes costs, including overhead and investments in infrastructure, while optimizing scientific capability to speed new tb drug development. Our business model and diverse partnerships allow tb alliance to leverage additional partner services for every dollar invested in its programs. Nc-009 - nc-009 is a pan-phase 2 clinical trial incorporating elements of phase 2a, b, and c to evaluate the safety and efficacy of a combination of a new experimental compound, tbaj-876, with pretomanid and linezolid, components of tb alliance's bpal regimen. This regimen has the potential to shorten and improve treatment for both drug-sensitive and drug-resistant forms of tb. Results from preclinical and phase 1 studies were presented at the 2023 union conference on lung health and showed that the new compound, tbaj-876, when compared with bedaquiline (a tb medicine in the same drug class), eliminated tb bacteria faster and had a potentially safer profile. Nc-009 will test different doses of tbaj-876 in combination with pretomanid and linezolid against the current standard of care for drug-sensitive tb - isoniazid, rifampicin, pyrazinamide, and ethembutol (hrze). Another arm of the trial will also test pretomanid and linezolid in combination with bedaquiline (bpal), a regimen now recommended by the world health organization to treat some forms of dr-tb, against drug-sensistive tb. The study enrolled apprximately 300 participants with drug-sensitive tb at 21 clinical trial sites in five countries: Georgia, philippines, south africa, tanzania, and uganda. Q203 - telacebec (q203) is a first-in-class drug candidate against mycobacterium tuberculosis infection. Q203 targets cytochrome bc1 complex and shows potent activity against multidrug-resistant tuberculosis (mdr-tb). Q203 has also been found effective against buruli ulcer (mycobacterium ulcerans), a chronic, necrotizing disease that affects skin and sometimes bone and can lead to permanent deformity and long-term disability, and leprosy (mycobacterium leprae). In 2023, tb alliance in-licensed q203 from qurient, a clinical-stage biotechnology company based in south korea. In july 2024, a phase 2 proof-of-concept study was initiated to explore the use of telacebec (q203) to treat buruli ulcer. If successful, a single drug could cut treatment duration by more than half. In partnership with tb alliance and with support from qurient co. Ltd, professor daniel o'brien - a prominent clinician-researcher and expert in buruli ulcer - is leading the study at barwon health and the royal melbourne hospital in australia. The trial will enroll approximately 40 adult patients with buruli ulcer who will receive 28 days of telacebec (300mg) once daily, followed by a year of observation. Preliminary results are expected in 2025. Tbaj-587 - this next-generation diarylquinoline project has shown potential to maintain bedaquiline's impressive anti-tb activities while retaining additional improved properties. Tbaj-587 is being studied through the innovative health initiative's era4tb project and, in 2024, tbaj-587 completed a phase i trial demonstrating positive results. Results publications are underway. Sutezolid - sutezolid is a promising clinical-stage tb drug candidate fro

Financial Efficiency

• Mission deployment rate: 91.5%; rating input score 92
• Program expense ratio: 88.5%; rating input score 88
• Fundraising efficiency: $38.84 raised per $1 spent on fundraising; rating input score 70; 70th percentile among comparable filings

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 68th percentile among comparable filings
• Pay-setting controls: 5 of 6 controls in place; rating input score 83
  • Compensation committee: Pass
  • Independent consultant: Pass
  • Other Form 990s reviewed: Pass
  • Written employment contract: Missing
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: 2 of 8 controls in place; rating input score 25
  • Claims monitoring procedures: Pass
  • Requires narrative reports: Limited
  • Conducts field audits: Limited
  • May suspend future funding: Limited
  • Requires financial reports: Limited
  • Conducts site visits: Limited
  • Requires grant agreements: Pass
  • May require repayment: Limited
• Grant itemization coverage: 100%; rating input score 100; 77th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 91.7%; rating input score 92; 40th percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 3.5%; rating input score 50; 50th percentile among comparable filings
• Total-asset coverage ratio: 3.32; rating input score 78; 78th percentile among comparable filings
• Liabilities to assets ratio: 0.14; rating input score 77; 77th percentile among comparable filings
• Officer compensation ratio: 11.4%; rating input score 2; 2nd percentile among comparable filings

Growth

• Program expense growth: -1.3% per year; rating input score 0; 5th percentile among comparable filings
• Revenue growth: -4.9% per year; rating input score 0; 1st percentile among comparable filings
• Asset growth: 11.1% per year; rating input score 100; 75th percentile among comparable filings